All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
HONG KONG – China's Ascletis Pharma Inc. and California-based 3-V Biosciences Inc. have inked a licensing deal for 3-V Biosciences' fatty acid synthase (FASN) inhibitor TVB-2640.